Laurus Labs Ltd is quoting at Rs 460.95, up 2.21% on the day as on 12:49 IST on the NSE. The stock is up 30.95% in last one year as compared to a 26.27% gain in NIFTY and a 44.18% gain in the Nifty Pharma index.

Laurus Labs Ltd soars 2.21%, Gains for third straight session

Citi has maintained a sell call on Ramco Cements, raising the target price to Rs 750 from Rs 735. Despite stable EBITDA per ton, Ramco has lost market share by not selling at significantly lower prices. The stock is expected to underperform until the company resolves the conflict between market share and pricing.

Hot stocks: Brokerage view on Ramco Cements, Tech Mahindra, Laurus Labs, Syngene and Cyient

Laurus Labs reports 53% profit decline in Q1, focusing on growth in Oncology API and CDMO opportunities.

Laurus Labs Q1 net slumps to ₹13 crore on lower revenue

Board of Laurus Labs appoints director

Laurus Labs consolidated net profit declines 49.66% in the June 2024 quarter

Upcoming results: Tech Mahindra, Nestle India, Motilal Oswal Financial Services, Aavas Financiers, Adani Green Energy, Ashok Leyland, AU Small Finance Bank, Canara Bank, Chalet Hotels, Chennai Petrochem Corp, Cyient, DLF, Glenmark Life Sciences, Go Digital General Insurance, Home First Finance Company India, Jupiter Wagons, Jyothy Labs, Laurus Labs, MGL, Mphasis, PNB Housing Finance, Praj Industries, The Ramco Cements.

Stock alert: Axis Bank, Larsen & Toubro, SBI Life Insurance Company, J K Paper, Bikaji Foods, Oracle Financal Services Software

Companies like Adani Energy, Ashok Leyland, Canara Bank, Chalet Hotels, Cyient, Glenmark Life, Laurus Labs, L&T Foods, Mahindra Holidays, PNB Housing Finance, Venus Pipes, Vivanta Industries among others will also declare their results

Q1 results today: Nestle, Tech Mahindra among 76 companies to announce earnings on Thursday

Laurus Labs Ltd is quoting at Rs 435.4, up 1.07% on the day as on 12:49 IST on the NSE. The stock is up 21.96% in last one year as compared to a 24.71% jump in NIFTY and a 44.98% jump in the Nifty Pharma index.

Laurus Labs Ltd up for third consecutive session

Laurus Labs fell 1.54% to Rs 427.85 after CARE Ratings revised its outlook on the long-term credit facilities of the company to ‘negative’ from ‘stable’ while affirming the rating on the same at “CARE AA”.

Laurus Labs edges lower after CARE Ratings downgrades rating outlook to ‘negative’

Here are all the top calls from analysts that you need to know about on Friday.

Brokerage Views: Citi On Ambuja Cements, Laurus Labs And More

Laurus Labs Ltd is quoting at Rs 444.2, up 0.12% on the day as on 12:44 IST on the NSE. The stock is up 29.35% in last one year as compared to a 25.46% jump in NIFTY and a 54.03% jump in the Nifty Pharma.

Laurus Labs Ltd spurts 0.12%, gains for fifth straight session

Price return has been average, nothing exciting

Performance

Seems to be overvalued vs the market average

Valuation

Lagging behind the market in financials growth

Growth

Showing good signs of profitability & efficiency

Profitability

The stock is overpriced but is not in the overbought zone

Current price is more than the intrinsic value

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

Laurus Labs Private Ltd is a research and development pharmaceutical company which manufactures active pharmaceutical ingredients (APIs) for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.

Laurus Labs Ltd